1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Valeant in joint venture with Meda

 
• By Simon Varcoe

Valeant Pharmaceuticalsis to form joint ventures with Medato develop, market and commercialise certain current and future products. This initially includes the insomnia treatment Sublinox (OX22) and flupertine, for the treatment of pain, in Australia, Canada and Mexico. The ventures will be mostly owned by Meda, with Valeant owning a minority interest. Valeant recently sold its eastern and western European businesses to Meda for $392 million (Scrip Online, August 5th, 2008).

Valeant Pharmaceuticalsis to form joint ventures with Medato develop, market and commercialise certain current and future products. This initially includes the insomnia treatment Sublinox (OX22) and flupertine, for the treatment of pain, in Australia, Canada and Mexico. The ventures will be mostly owned by Meda, with Valeant owning a minority interest. Valeant recently sold its eastern and western European businesses to Meda for $392 million (Scrip Online, August 5th, 2008).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Lilly To Diversify Pain Pipeline With SiteOne Acquisition

 
• By Joseph Haas

Deal snapshot: With several internal non-opioid pain candidates in Phase II or earlier, Lilly looks to add R&D potential in pain with $1bn buyout of SiteOne.

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

More from Therapeutic Category

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.

Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS

 
• By Jessica Merrill

Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise

 
• By Andrew McConaghie

The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.